Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
- Authors: Iannitto, Emilio; Ferrero, Simone; Bommier, Côme; Drandi, Daniela; Ferrante, Martina; Bouabdallah, Krimo; Carras, Sylvain; Gini, Guido; Camus, Vincent; Mancuso, Salvatrice; Marcheselli, Luigi; Ferrari, Angela; Merli, Michele; Tessoulin, Benoit; Stelitano, Caterina; Beldjord, Kheira; Roti, Giovanni; Jardin, Fabrice; Castagnari, Barbara; Palombi, Francesca; Baseggio, Lucile; Traverse-Glehen, Alexandra; Tripodo, Claudio; Liberati, Anna Marina; Parolini, Margherita; Usai, Sara; Patti, Caterina; Federico, Massimo; Musso, Maurizio; Ladetto, Marco; Zucca, Emanuele; Thieblemont, Catherine
- Publication year: 2024
- Type: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/639738
Abstract
: Not available.